• Citer

348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

par Eiger, Daniel;Maurer, Christian;Brandão, Mariana ;Aftimos, Philippe ;Punie, Kevin;Taylor, D.;Van den Mooter, Tom;Poncin, R.;Canon, Jean-Luc;Duhoux, Francois P;Casert, Vinciane;Clatot, F.;Velghe, Chloé;Craciun, Ligia;Paesmans, Marianne ;de Azambuja, Evandro ;Ignatiadis, Michail ;Larsimont, Denis ;Piccart-Gebhart, Martine ;Buisseret, Laurence
Référence Annals of oncology, 31, page (S386-S387)
Publication Publié, 2020-09

Article révisé par les pairs

• Accès en ligne
• Détails
• Statistiques

Titre:	348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Auteur:	Eiger, Daniel; Maurer, Christian; Brandão, Mariana; Aftimos, Philippe; Punie, Kevin; Taylor, D.; Van den Mooter, Tom; Poncin, R.; Canon, Jean-Luc; Duhoux, Francois P; Casert, Vinciane; Clatot, F.; Velghe, Chloé; Craciun, Ligia; Paesmans, Marianne; de Azambuja, Evandro; Ignatiadis, Michail; Larsimont, Denis; Piccart-Gebhart, Martine; Buisseret, Laurence
Informations sur la publication:	Annals of oncology, 31, page (S386-S387)
Statut de publication:	Publié, 2020-09
Sujet CREF:	Cancérologie
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1016/j.annonc.2020.08.450
	info:pii/S0923753420404466